We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Epigenetic Similarity in Cancer Cells Characterizes More Aggressive Tumors

By LabMedica International staff writers
Posted on 29 Aug 2016
Print article
Image: A microscopic view of a colon cancer section (Photo courtesy of IDIBELL-Bellvitge Biomedical Research Institute).
Image: A microscopic view of a colon cancer section (Photo courtesy of IDIBELL-Bellvitge Biomedical Research Institute).
Cancer researchers have found that the degree of epigenetic similarity among colorectal tumor cells was reflected in patients as significantly shortened relapse-free survival time and shortened time of overall survival.

Few biomarkers for predicting outcomes of patients with colorectal cancer have been validated. This is in part due to the genetic and molecular heterogeneity of colorectal tumors not only among different patients, but also within the tumors themselves.

To better understand the puzzle of tumor cell heterogeneity, investigators at IDIBELL-Bellvitge Biomedical Research Institute (Barcelona, Spain) analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of 79 colorectal tumors and 23 associated liver metastases, obtained from two hospitals in Spain. They also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses.

Results showed that among three defined tumor sections, differences in DNA methylation were most pronounced at the site of the tumor-host interface. Tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When individual coefficients were calculated to quantify heterogeneity, epigenetic homogeneity was found to be significantly associated with short time of relapse-free survival and short time of overall survival.

"In patients with colorectal cancer, we determined the epigenome of three regions of each individual tumor. The area looking at the beginning of the digestive tract, central and growing into the blood vessels results demonstrate the existence of intratumoral heterogeneity, which means that each region has differences," said senior author Dr. Manel Esteller, director of the epigenetics and cancer biology program at Bellvitge Biomedical Research Institute. "The more epigenetically different region is the invasive front, the area that interacts with adjacent normal tissues. We have also seen that the intratumoral region most similar to metastatic stages is the oldest of the tumor, which suggests spreading even in apparently early stages. Furthermore, data show that the more similar the three regions are, the more aggressive the tumor is, just as if the cell population with more proliferation capacity had already been selected. Measurements of the level of molecular heterogeneity of tumors could then be used as predictors of their prognosis and potential to acquire resistance to therapies."

The study was published in the August 10, 2016, online edition of the journal Gastroenterology.

Related Links:
IDIBELL-Bellvitge Biomedical Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more